Balancing the upside and downside of antiretroviral therapy in children

JAMA

Volumn 293, Issue 18, 2005, Pages 2272-2274

  Yogev, Ram ^a  

^a CHILDREN'S MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ZIDOVUDINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

CHILD HEALTH CARE; DRUG SURVEILLANCE PROGRAM; EDITORIAL; HEALTH CARE ORGANIZATION; HEALTH PROGRAM; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; INFECTION RISK; PERINATAL INFECTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROPHYLAXIS; QUALITY CONTROL; VIRUS RESISTANCE; ADOLESCENT; CHILD; INFANT; MORTALITY; NEWBORN; NOTE; PRESCHOOL CHILD;

ADOLESCENT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD; CHILD, PRESCHOOL; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN;

EID: 18244390959     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.293.18.2272     Document Type: Editorial

References (25)

1. Berk DR, Falkovitz-Halpern MS, Hill DW, et al. Temporal trends in early clinical manifestations of perinatal HIV infection in a population-based cohort. JAMA. 2005;293:2221-2231.
2. Brogly S, Williams P, Seage GR III, et al. Antiretroviral treatment in pediatric HIV infection in the United States: from clinical trials to clinical practice. JAMA. 2005;294:2213-2220.
3. Idemyor V. Continuing debate over HIV therapy initiation. HIV Clin Trials. 2002;3:173-176.
4. Hainaut M, Peltier CA, Gerard M, et al. Effectiveness of antiretroviral therapy initiated before the age of 2 months in infants vertically infected with human immunodeficiency virus type 1. Eur J Pediatr. 2000;159:778-782.
5. Luzuriaga K, McManus M, Mofenson L, et al. A trial of three antiretroviral regimens in HIV-1-infected children. N Engl J Med. 2004;350:2471-2480.
6. Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21-30.
7. Howard AA, Arnsten JH, Lo Y, et al. Prospective study of adherence and viral load in a large multi-center cohort of HIV-infected women. AIDS. 2002;16:2175-2182.
8. Van Dyke RB, Lee S, Johnson GM, et al. Reported adherence as a determinant of response to highly active antiretroviral therapy in children who have human immunodeficiency virus infection. Pediatrics. 2002;109:e61.
9. Watson DC, Farley JJ. Efficacy of and adherence to highly active antiretroviral therapy in children infected with human immunodeficiency virus type 1. Pediatr Infect Dis J. 1999;18:682-689.
10. Belzer ME, Fuchs DN, Luftman GS, Tucker DJ. Antiretroviral adherence issues among HIV-positive adolescents and young adults. J Adolesc Health. 1999;25:316-319.
11. Wu AW, Ammassari A, Antinori A. Adherence to antiretroviral therapy: where are we, and where do we go from here? J Acquir immune Defic Syndr. 2002;31(suppl 3):S95-S97.
12. Mitty JA, Stone VE, Sands M, et al. Directly observed therapy for the treatment of people with human immunodeficiency virus infection: a work in progress. Clin Infect Dis. 2002;34:984-990.
13. Rogers AS, Miller S, Murphy DA, et al. The TREAT (Therapeutic Regimens Enhancing Adherence in Teens) program: theory and preliminary results. J Adolesc Health. 2001;29(3 suppl):30-38.
14. Lyon ME, Trexler C, Akpan-Townsend C, et al. A family group approach to increasing adherence to therapy in HIV-infected youths: results of a pilot project. AIDS Patient Care STDS. 2003;17:299-308.
15. World Health Organization. Scaling Up Antiretroviral Therapy in Resource-Limited Settings. April 2002. Available at: http://www.emro.who.int/ asd/BackgroundDocuments/InternationalHIVTreatment-Summary.pdf. Accessibility verified April 14, 2005.
16. Krogstad P, Wiznia A, Luzuriaga K, et al. Treatment of human immunodeficiency virus 1-infected infants and children with the protease inhibitor nelfinavir mesylate. Clin Infect Dis. 1999;28:1109-1118.
17. Nachman SA, Stanley K, Yogev R, et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. JAMA. 2000;283:492-498.
18. Treat 3 Million by 2005 Initiative, World Health Organization. Treating 3 Million by 2005: Making It Happen - the WHO and UNAIDS Global Initiative to Provide Antiretroviral Therapy to 3 Million People With HIV/AIDS in Developing Countries by the End of 2005. Available at: http://www.who.int/3by5/ publications/documents/isbn9241591129/en/. Accessibility verified April 14, 2005.
19. Sriskandabalan PS. Self-medication with zidovudine that was not. Lancet. 2001;357:1370.
20. World Health Organization. Three AIDS medicines will be removed from the prequalification list this week. August 4, 2004. Available at: http://www.who.int/mediacentre/news/releases/2004/pr53/en/. Accessed February 3, 2005.
21. Adje C, Cheingsong R, Roels TH, et al. High prevalence of genotypic and phenotypic HIV-1 drug-resistant strains among patients receiving antiretroviral treatment in Abidjan, Cote d'Ivoire. J Acquir Immune Defic Syndr. 2001;26:501-506.
22. Institute of Medicine Committee on Perinatal Transmission of HIV. Reducing the Odds: Preventing Transmission of HIV in the United States. Washington, DC: National Academy Press; 1998.
23. HIV testing among pregnant women - United States and Canada, 1998-2001. MMWR Morb Mortal Wkly Rep. 2002;51:1013-1016.
24. Centers for Disease Control and Prevention. Progress toward elimination of perinatal HIV infection, Michigan, 1993-2000. MMWR Morb Mortal Wkly Rep. 2002;51:93-97.
25. Byers RH Jr, Caldwell BM, Davis S, Gwinn M, Lindegren ML. Projection of AIDS and HIV incidence among children born infected with HIV. Stat Med. 1998;17:169-181.